

## References

### I-58

1. Doerfler P, Nayak S, Corti M, et Targeted approaches to induce immune tolerance for Pompe disease therapy. *Mol Ther Methods Clin Dev.* 2016; 3:15053.
2. Polinski JM, Kowal MK, Gagnon M, et Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare.* 2016.
3. MICROMEDEX®SOLUTIONS 2017. Alglucosidase alfa.
4. Clinical Pharmacology [database online]. Tampa FL: Gold Standard, Inc. Alglucosidase alfa.
5. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
6. van der Meijden JC, Kruijshaar ME, Harlaar L, et al. Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy. *J Inherit Metab Dis.* 2018; 41(6):1205-14.
7. Byrne BJ, Fuller DD, Smith BK, et al. Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy. *Ann Transl Med.* 2019; 7(13).
8. Parini R, De Lorenzo P, Dardis A, et al. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy. *Orphanet J Rare Dis.* 2018; 13(1):32.
9. Confalonieri M, Vitacca M, Scala R, et al. Is early detection of late-onset Pompe disease a pneumologist's affair? A lesson from an Italian screening study. *Orphanet J Rare Dis.* 2019; 14(1):62.